# Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients

> **NCT01817868** · — · COMPLETED · sponsor: **Bayer** · enrollment: 73 (actual)

## Conditions studied

- Hemophilia

## Interventions

- **OTHER:** Recombinant Factor VIII (Kogenate, BAY14-2222)

## Key facts

- **NCT ID:** NCT01817868
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-04
- **Primary completion:** 2018-07-16
- **Final completion:** 2019-05-23
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2020-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01817868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01817868, "Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01817868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*